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Summary. This paper serves as a framework for designing advanced models for
drug action on metabolism. Drug treatment may affect metabolism by either enhanc-
ing or inhibiting metabolic reactions comprising a metabolic network. We introduce
the concept of metabolic graphs, a generalization of hypergraphs having specialized
features common to metabolic networks. Linear-in-flux-expression (briefly LIFE) is
a methodology for analyzing metabolic networks and simulating virtual patients. We
extend LIFE dynamics to be compatible with metabolic graphs, including the more
complex interactions of enhancer and inhibitor molecules that affect biochemical re-
actions. We discuss results considering network structure required for existence and
uniqueness of equilibria on metabolic graphs and show simulations of drug action
on Mycobacterium tuberculosis (briefly MTB).
1.1 Introduction
The modeling of metabolic networks plays a crucial role in systems biology and has
many diverse applications, including in Quantitative Systems Pharmacology [29] for
drug discovery and optimization of drug treatments. There are various challenges at
modeling, including the complexity and dimensionality of the involved networks, of-
ten times comprising hundreds of metabolites and thousands of reactions, enzymes
and genes. For this reason, only methods corresponding to linear dynamics pre-
sented the characteristic of scalability and computability to address such problems.
In this area, Flux Balance Analysis (briefly FBA) plays a special role for its sim-
plicity and many successful uses, see [13, 18, 21, 27, 31]. Other linear techniques
proved efficient, such as zero deficiency theory, Markov chains, Laplacian dynamics
[1, 5, 7, 10, 14, 15].
Beside the limitation of dealing only with linear dynamics, such methods mostly
neglected the nonlinear effects related to the action of enzymes, the regulation ef-
fect of genes and the action of drugs on genes. In mathematical terms, even if one
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accepts a linear dynamics in terms of the metabolites, the action of enzymes, genes
and drugs affects fluxes among metabolites. For the example of a downregulation
action of a gene, then reducing a flux would necessarily correspond to a nonlinear
term in the dynamics of the involved metabolites. Even more, such action cannot
be represented in the usual language of graph theory, thus requiring the use of more
general theories.
The present paper addresses such limitations using two main tools:
1. A new representation of metabolite dynamics called Linear-In-Flux-Expression
(briefly LIFE) to allow nonlinearities in the dynamics.
2. The use of metabolic graphs, based on hyper and uber-graphs, to allow the repre-
sentation of enzymes, genes and drug action.
The rest of this Introduction details the two main methods and provides a brief
description of our main application: the action of antibiotics on the Mycobacterium
tuberculosis (briefly MTB).
The paper is organized as follows. Section 1.2 discuss the LIFE approach and
provide basic definition, while in Section 1.2.1 we illustrate the central carbon
metabolism network of MTB. In particular the example shows the necessity of in-
troducing the concept of metabolic graph which is done in Section 1.3. Extension of
LIFE to metabolic graphs is done in Section 1.4 and the problem of existence and
uniqueness of equilibria is explored in Section 1.4.1. Application of the methods to
drug action on MTB (specifically synthesis of antibiotics) is illustrated in Section
1.5.
1.1.1 The LIFE method
Recently, flux balance analysis techniques were expanded to include nonlinear
metabolite dynamics. More precisely the usual way to write the dynamics of a
metabolic network is:
x˙ = S(f) · x, (1.1)
where x ∈ Rn is the vector of metabolite levels, f ∈ Rm the vector of fluxes and
S is a n × n matrix, called stoichiometric matrix, which link the flux levels to the
metabolite dynamics. The system is linear in the metabolites and usually the system
is represented by a directed graph G = (V,E), with V the set of vertices (or nodes)
representing metabolites and E ⊂ V ×V the set of edges, representing fluxes linked
to biochemical reactions.
Often times the metabolite dynamics may be nonlinear, e.g. given by a Michaelis-
Menten-type kinetics, however the linearity in the fluxes is essentially given by def-
inition. Moreover, many important biological and mathematical problems can be
formulated in terms of the fluxes levels, which usually are assumed to be constant
or evolve by slow dynamics or, finally, modified by drug intervention. Thus the main
idea behind the Linear-In-Flux-Expression approaches (briefly LIFE) is to write the
system as:
x˙ = S(x) · f, (1.2)
where x and f are as before, but the new stoichiometric matrix S = {Sve}v∈V,e∈E
is now an n × m matrix explicitly encoding the linear behavior in the fluxes. A
typical advantage is the possibility of consider nonlinear dynamics allowing Sve to be
nonlinear in x and exploring the space of equilibria as function of fluxes, given by the
kernel of the matrix S. General conditions on network topology (connection of every
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node to excretion, see [25]) guarantee existence and uniqueness of an equilibrium x¯f
for every flux vector f = {fe}, thus network asymptotic dynamics is captured by the
map f → x¯f . We will provide more detail below about the many results achievable
by this approach combining several different methods for modeling chemical systems,
including systems biology, zero deficiency theory, laplacian dynamics, and Markov
chains [28, 1, 5, 15, 10, 14, 7]. We will also refer the reader to [2, 24, 25] for a general
presentation of the LIFE approach.
1.1.2 Hyper, uber and metabolic graphs
As explained above FBA and other methods rely on representing the metabolic
network as a directed graph, where edges represent biochemical reaction. There are
(at least) three main limitations related to representing a complex metabolic network
with a standard directed graph and these are:
1. Most networks include inflows and outflows (also called intakes and excretions in
LIFE methodology) to the external environment or to other networks. Virtual nodes
to represent such flow must be included or, alternatively, one must include directed
edges with a node only on one end.
2. Some biochemical reactions necessarily involve more than two metabolites, e.g.
when two or more compounds interact to form a set of other compounds. Therefore
edges with multiple entering and exiting nodes must be included.
3. The action of enzymes, genes and drugs often times affect a specific reaction
acting as enhancer or inhibitors. Such actions can be represented by edges joining a
node to another edge.
All these extensions can be achieved by introducing appropriate generalization of
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Fig. 1.1: We define a metabolic graph to have two added features compared to simple
directed graphs: 1. Left weighted hyperedge h will replace simple edges. These edges
have weights assigned to each branch of the hyperedge respecting the stoichiometry
of the corresponding reaction; and 2. Right enhancer or inhibitor dynamics acting
on edge e. The inhibitor (enhancers) are included to model the action of molecules
inhibiting (promoting) the enzyme for a reaction corresponding to edge e. The edges
u1, u2 are called uberedges and connect a node to an edge.
the concept of graph. In particular hypergraphs [4, 35] contain hyperedges with
multiple nodes, ubergraphs [16] include uberedges connecting node to other edges.
We use this tool to defined a generalized graph, called metabolic graph addressing the
limitations 1-3. Figure 1.1 depicts the main idea behind the definition of metabolic
graph. Metabolic graphs are hypergraphs which may include an uberedge which
connects a node to a hyperedge.
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1.1.3 Tuberculosis
The Mycobacterium tuberculosis (briefly MTB) has infected thirty percent of the
world’s population according to the World Health Organization(WHO). The WHO
declared tuberculosis (brifely TB) a global emergency in 1993 [26]. The bacterium
is known to endure hostile environments within the host organism through two
main factors 1. genetically diverse sub-populations [6, 3] and 2. a sophisticated
gene regulatory network(briefly GRN) [3, 12, 30]. Developing new TB drugs with
improved effectiveness depends on modelling MTB in multiple metabolic states.
In the past, designing treatment for TB has been exceptionally difficult, often
requiring drug cocktails of up to four different drugs. In addition to multiple drugs,
treatment may last up to six months, and this duration along with complications due
to drug side effects can negatively effect patient compliance. Two main approaches
have been taken to improve TB treatment. the first approach is discovering more
effective dosing regimens of these drug cocktails [8, 23, 34]
The second approach is to anticipate the response of the GRN to treatment[33,
19, 9]. This allows one to exploit the changing metabolism of MTB, but requires
accurate models of the response to drug treatment. Such models of MTB metabolism
are difficult to construct due to the numerous complex effects of the GRN on the
metabolic state as a consequence of environmental or internal chemical conditions.
In either approach, it is essential to model the individual drug interactions care-
fully so that a model can be built with a solid foundation. Modeling drug interactions
in an intuitive way requires us to allow structures where molecules or metabolites
inhibit or enhance a biochemical reaction. This action can be depicted as a node at-
tached to a hyperedge (connecting nodes which represent multiple reactant metabo-
lites to nodes representing products of the reaction).
1.2 Modeling metabolic networks with LIFE
Generalizing the dynamics of FBA, we focus on the following class of systems:
x˙ = S(x) · f, (1.3)
where the stoichiometric matrix S is as in FBA models, but depending on x, and f is
the column vector of fluxes. The values x1, x2 . . . represent mass of metabolties and
so are constrained to R+. The network is associated to a directed graph G = (V,E),
with V = {v1, . . . , vn} the set of nodes and E ⊂ V × V the set of directed edges.
Sve(x) indicates the matrix entry corresponding to node v and edge e. The network
equilibria correspond to the null space of S(x) thus depend both on the fluxes
and metabolite levels and a detailed analysis is provided in [25] combining various
mathematical approaches as follows. Linear systems without intakes nor excretions
are related to continuous-time Markov chains [7], while linear systems with intakes
and excretions are known as compartmental systems [5, 15]. Nonlinear systems could
be treated by using the results of [22]. Metabolic networks contain exchange fluxes
representing incoming mass from other parts of the network, or from the outside
environment, and they are necessary for the existence of equilibria. For traditional
metabolic networks described by a directed graph G = (V,E), directed edges from a
virtual node v0 which acts as a source to some node in the graph are called intakes,
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and edges from a node in the graph to some virtual node vn+1 acting as a sink are
called excretions.
Definition 1. Given a directed graph G = (V,E), an edge (v0, v1) ∈ E for the
virtual node v0, the edge (v0, v1) is called an intake, and v1 is an intake node. For
the virtual node vn+1 an edge (vj , vn+1) is called an excretion, and vj is an excretion
node. The set of intake nodes is denoted I, and the set of excretion nodes is denoted
by J .
A general assumption, still allowing significant results, is the following:
(H1) Sve(x) =

−Fe(xv) e = (v, w), v ∈ V,w ∈ V ∪ {vn+1}
Fe(xw) e = (w, v), w ∈ V
1 e = (v0, v) v ∈ I
0 otherwise,
where Fe : R+ → R+ is differentiable, strictly increasing, with Fe(0) = 0, for
R+ = {x ∈ R : x ≥ 0}. (H1) is a natural assumption on the system; the flow from a
metabolite will depend only on that metabolite, but for a metabolite with multiple
edges may have different kinetics with each reaction. This assumption also includes
nonlinear kinetics such as Michaelis-Menten [20] corresponding to Hill functions
Fv(xv) =
xpv
K+x
p
v
with p ∈ N. Moreover, all columns of S have zero sum, except those
corresponding to intakes and excretions, which have positive and negative sum,
respectively. Therefore, the dynamics (1.3) can be interpreted as mass conservation
law. To be biologically meaningful, we further restrict to equilibria for which all
components of f and x are positive, thus rendering the problem nonlinear even for
linear dynamics. A previous result shows that under (H1), the existence of equilibria
depends on the structure of the network.
Proposition 1. Consider a system (1.3) satisfying (H1). Assume there exists an
equilibrium x¯ ∈ (R+)n for a flux vector f such that fe > 0 for every e ∈ E˜. Then
for every node v ∈ V for which there exists a path from I to v, there exists a path
from v to J .
This proposition is proven in [25]. We extend these results to metabolic networks
including enhancers and inhibitors as explained in Section 1.3.
1.2.1 Central Carbon Metabolism in Mycobacterium tuberculosis
The dynamics described in the previous section can be used to model the flows of
a metabolic network. The entries of the stoichiometric matrix describe the mass
flowing along an edge of the network per time. The flux for each edge represents the
speed of this flow. We present an example metabolic network from [32] to motivate
expanding the LIFE method from section 1.2.
The Metabolic network shown in Figure 1.2 is the central carbon metabolism of
MTB derived from an infection in mouse. The network shown is a metabolic network
of MTB in a state of growing bacilli. This network depicts carbon from lipid and
sugar catabolism used by MTB for generating energy and biosynthetic precurors
required for growth. Specifically glucose is a product of catabolism and the cell uses
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this energy to synthesize enzymes for the pentose phosphate pathway and provide
ribose 5-P for nuclotide synthesis. Glycolysis yields metabolites phosphoenolpyru-
vate(PEP), Pyruvate, and acetyl-CoA. Experiments showed that MTB preferentially
uses fatty acids as a carbon source. When MTB is in the “non-growing” state within
mouse infection, some of the genes required for this process are known to be upreg-
ulated. These observations led to the proposal that MTB switches its carbon source
from sugars to fatty acids during the persistent phase of infection.
α-ketoglutarate
isocitrateoxaloacetate
malate
succinate
acetyl CoApyruvatePEPglucose
glyoxylate
acetyl CoA
v0
v12
Clofazimine
h1,2
h3
h1,2 = h1 and h2
Fig. 1.2: The central carbon metabolism of Mycobacterium tuberculosis with
TB drug action shown. The well known drug Clofazimine inhibits the reac-
tion which oxidizes malate. The edges labeled h1,2 represents two different
hyperedges, and h3 is a third hyperedge connecting three metabolites.
Simple directed edges, as in standard graphs, model most reactions in carbon
metabolism. However, the complete dynamics involves several hyperedges, i.e. gen-
eralized edges connecting more than two nodes. The hyperedge labeled h1,2 consists
of two distinct directed hyperedges, each connecting three metabolites involved in
a single chemical reaction (the first having two reactants and the second having
two products). The details about the reactions are taken from the KEGG database
[17]. In particular, h1 describes a chemical reaction producing isocitrate from Ox-
aloacetate, and acetyl CoA, and h2 uses isocitrate to produce acetyl CoA and ox-
aloacetate. The third hyperedge h3 models acetyl CoA reacting with glyoxylate to
produce malate. We also included the drug Clofazimine, which acts as an inhibitor
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on the malate-oxaloacetate reaction.
The need to describe reactions depicted by the hyperedges and inhibitor in Figure 1.2
is what brings us to metabolic graphs and extending the LIFE method accordingly.
1.3 Metabolic graphs
To model intakes, excretions, general biochemical reactions, inhibitors and enhancers
acting on a metabolic network, we will introduce a new mathematical object called
a metabolic graph. Metabolice graphs are a subclass of ubergraph, a generalization
of hypergraphs introduced in [16] (here we use a different definition of ubergraph
stated in the Appendix).
Directed graph are commonly used to model metabolic networks, with nodes
representing metabolites and edges representing the biochemical reactions. A hy-
pergraph is a more general structure where an edge can connect more than two
nodes. For the following definitions, let V = {v1, . . . , vn} be a set of nodes and let
P(V ) be the power set of V .
Definition 2. A hyperedge h is a set of nodes connected to each other, i.e. h ∈
P(V ) \ {∅}. Note that the set h = {vi} indicates a loop edge connecting vi to itself.
Because chemical reactions of a metabolic network indicate a direction of flow, we
require hypergraphs to include direction.
Definition 3. A directed hyperedge is an ordered pair of two subsets of nodes, i.e.
h = (X,Y ) with X ∈ P(V ) or X = {v0}, Y ∈ P(V ∪ {vn+1}), where v0 (vn+1) is
a virtual node called the source (sink). Elements of X (Y ) are called initial nodes
(terminal nodes) for the hyperedge h. The set of directed hyperedges is denoted H.
When using a hyperedge to model reacting metabolites forming a product, we encode
the stoichiometry relationship on the a hyperedge via edge weights. It is convenient
to have notation for the cardinality of the sets of initial and terminal nodes for a
hyperedge.
Definition 4. Given a directed hyperedge h = (X,Y ), with X,Y ∈ P(V ), the inde-
gree of h is defined as
din(h) = |X|, (1.4)
and the outdegree of h is defined as
dout(h) = |Y | (1.5)
where | · | indicates the cardinality of a set.
Definition 5. A weighted directed hyperedge is a couple H 3 h = (X,Y ) with X ∈
P(V ) or X = {v0}, Y ∈ P(V ∪ {vn+1}), and corresponding weights Ψh : h 7→
(Ψouth , Ψ
in
h ) where Ψ
out
h : X 7→ R+ and Ψ inh : Y 7→ R+.
We are now ready to describe a mathematical representation of inhibitors and en-
hancers. More precisely, we want to consider metabolites influencing a given reaction.
This can be captured by new type of generalized edges, called an uberedge linking
nodes to directed hyper edges.
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Definition 6. An e/i-uberedge is a couple u = (v, h) with v ∈ V, h ∈ H. We denote
the set of e/i-uberedges by U .
We are now ready to provide the definition of metabolic graph. For a complete
description of a metabolic networks, uberedges are endowed with a sign to indicate
their action as enhancer (+) or inhibitor (−). This subset of uberedges from a node to
a hyperedge are depth 2 uberedges according to the general definition of ubergraph
(see Appendix).
Definition 7. A metabolic graph is a weighted directed hypergraph endowed with
signed depth-2 uberedges connecting nodes to hyperedges. More precisely, a metabolic
graph is an ordered quintuplet G = (V,H,U , ΨH, ΨU ) where V = {v1, . . . , vn} is
the set of nodes, H is the set of directed hyperedges, ΨH = {Ψh : h ∈ H} is the
set of functions assigning weights to hyperedges, U is the set of e/i-uberedges and
ΨU : U 7→ {+,−}.
Definition 8. Given a metabolic graph G, a path is a sequence of distinct nodes
vi1 · · · vik , with (vij ∈ X, vij+1 ∈ Y ) and (X,Y ) ∈ H for j = 1, . . . , k − 1. A graph
is strongly connected if there exists a path between every pair of nodes. A strongly
connected component of a directed graph is a maximal strongly connected subgraph.
A terminal component of a metabolic graph G is a strongly connected component
corresponding to a subset of nodes V ′ ⊂ V , such that for v′ ∈ V ′ and v ∈ V \ V ′
there exists no hyperedge h = (X,Y ) with v′ ∈ X and v ∈ Y .
Definition 9. Given a metabolic graph G, Intakes ( Excretions) are hyperedges
(X,Y ) such that X = {v0} (vn+1 ∈ Y ). Intake nodes are nodes v ∈ V such that
there exits a hyperedge (X,Y ) with X = {v0} and v ∈ Y . Excretion nodes are nodes
v ∈ V such that there exits a hyperedge (X,Y ) with v ∈ X and vn+1 ∈ Y . We
indicate by I the set of intake nodes and by J the set of excretion nodes.
1.3.1 Central Carbon Metabolism
Let us go back to the central carbon metabolism network of MTB represented in Fig-
ure 1.2. This network can be described by a metabolic graph G = (V,H,U , ΨH, ΨU )
as follows. The set V of nodes is given by:
V = {v1, . . . , v11} = {glucose,PEP, pyruvate, acetyl CoA, isocitrate, oxaloacetate,
glyoxylate,malate, α− ketoglutarate, succinate,Clofazimine}.
The set of hyperedges H contains regular edges and three directed hyperedges:
h1 = ({acetyl CoA, oxaloacetate}, {isocitrate}),
h2 = ({isocitrate}, {acetyl CoA, oxaloacetate}),
and h3 = ({acetyl CoA, glyoxylate}, {malate}).
The set of uberedges U has only one uberedge:
u1 = (Clofazimine, ({malate}, {oxaloacetate})).
For simplicity the functions ΨH, ΨU are not listed, but can be deduced from the
KEGG database [17].
This graph is more descriptive of important functions of drug action on the metabolic
network, and it contains three hyperedges and a single uberedge. Each of the hyper-
edges combines three metabolites; h1,h3 have two reactants and one product whereas
h2 has two reactants and one product. The uberedge shown from Clofazimine to the
malate-oxaloacetate reaction indicates the well known TB drug “Clofazimine” acts
as an inhibitor on a reaction which oxidizes malate.
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1.4 Metabolic dynamics with inhibitors and enhancers
In the treatment of TB, drugs will act as enhancers and inhibitors to various edges
in the network, and so will appear as uberedges. In this section we define how en-
hancers and inhibitors affect the dynamics as well as equilibria conditions. In order
to include enhancers and inhibitors (which serve as the initial nodes for uberedges)
we introduce a new assumption:
(H2) We assume that for every node v and hyperedge h = (X,Y ), with v ∈ X, the
following holds. Let Uh be the set of nodes w such that there exists e/i-uberedge
(w, h) ∈ U , then we have:
Svh(x) =

−αv · Fh(x) ·Kh(x) v ∈ X
αv · Fh(x) ·Kh(x) v ∈ Y
1 X = {v0}, v ∈ Y,
0 otherwise,
(1.6)
where αw = Ψ
in
h (w) if w ∈ X and αw = Ψouth (w) if w ∈ Y are the stoichiometric
coefficients, Fh : Rdin(h) → R+ is given by
Fh(x) = min
w∈X
{
Fw,h(xw) · 1
αw
}
, (1.7)
Fw,h : R+ → R+ quantifies the potential flow of metabolite xw due to reaction h,
and
Kh =
∏
w∈Uh
K(w,h)(xw), (1.8)
where K(w,h) : R+ → R+ quantifies the action of metabolite xw on h, with the
convention that Kh = 1 if Uh = ∅.
The stoichiometric coefficients αw ∈ R for the reaction corresponding to hyperedge
hare normalized such that
∑
w∈X αw = 1 and
∑
w∈Y αw = 1. The functions Fw,h,
w ∈ Y are continuously differentiable. The functions K(w,h), w ∈ Uh, are continu-
ously differentiable, monotonic with K(w,h)(0) = 1. More precisely if ΨU ((w, h)) = +
then K(w,h) is increasing (enhancer case), othwerwise K(w,h) is decreasing (inhibitor
case).
Similarly to (H1), under assumption (H2) each function Fw,h depends only on the
metabolite xw, but there is the additional factor K which corresponds to the action of
one or more e/i-uberedges. This gives a nonlocal dependence, with respect to network
topology, because the node(s) corresponding to an enhancer(s) or inhibitor(s) may
be anywhere in the network not necessarily close to the edge it is affecting.
We are ready to state our first result:
Proposition 2. Consider a system (1.3) satisfying (H2). Assume there exists an
equilibrium x¯ ∈ (R+)n for a flux vector f such that fh > 0 for every h ∈ H. Then
for every node v ∈ V for which there exists a path from the intake nodes to v, there
exists a path from v to the excretion nodes.
Proof. Assume there exists an equilibrium x¯ ∈ R+n and, by contradiction, a node v
for which there exists a path from w, an intake node, to v, but there exists no path
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from v to some excretion node. Since there is no path from v to excretion nodes,
either v belongs to a terminal component, or there is a path from v to a terminal
component with no excretion. Denote by VT ⊂ V the set of nodes of such a terminal
component. Since there is a path from w, an intake node, to v and a (possibly trivial)
path from v to VT , then there is also a path from intake nodes to VT . Denote by
v0, v1 = w, . . . , v`−1, v` one such a path, such that v`−1 /∈ VT and v` ∈ VT (possibly
the path is a single hyperedge, in the case with w ∈ VT ).
It is easy to show that xvi > 0 for all i = 1, . . . , `, as follows. If h = (X,Y ) with
v0 ∈ X, v1 ∈ Y , then by (H2) we have Sv0,h(x¯) = 1. On the other side, for every
h′ = (X,Y ) with v1 ∈ X,w′ ∈ Y , xv1 = 0 implies Sv1,h′(x) = 0. Consequentially
xv1 = 0 implies x˙v1 ≥ αv1fhFh(x¯) > 0 (where h = (X,Y ) with v0 ∈ X, v1 ∈ Y ),
contradicting x¯ being an equilibrium. Having proved that x¯v1 > 0, we can proceed by
induction: for i = 1, . . . , `− 1, x¯vi > 0 implies x¯vi+1 > 0. The argument is the same
as above, with a slight modification: looking at h = (X,Y ) with vi ∈ X, vi+1 ∈ Y ,
Svi+1,h(x¯) = αv · Fh(x¯) · Kh(x¯) > 0 thanks to (H2) together with x¯i > 0, while
above we were in the case of an intake.
Finally we have a terminal component with no excretion, and a hyperedge h =
(X,Y ) with v`−1 ∈ X, v` ∈ Y with v` ∈ VT and v`−1 /∈ VT , such that either v`−1 = v0
or x¯v`−1 > 0. In either case, considering h˜ = (X,Y ) with v`−1 ∈ X, v` ∈ Y , by (H2)
we have Sv`,h˜(x¯) = αv` · Fh˜(x¯) · Kh˜(x¯) > 0. Now consider the variation of mass
in the nodes of the component VT : since there are no hyperedges leaving VT , and
there is at least the incoming hyperedge h˜, we have d
dt
∑
v∈VT xv =
∑
v∈VT x˙v ≥
αv` · Fh˜(x¯) ·Kh˜(x¯)fh˜ > 0, contradicting the fact that x¯ is an equilibrium. uunionsq
For a system with fixed metabolites, the existence of feasible flows will depend on
network structure. The Max-flow-min-cut Theorem [11] implies that a feasible flow
exists if there is a path from intakes to excretions, and indeed this Theorem holds
true also for metabolic graphs providing suitable definitions.
Definition 10. A flow on a metabolic graph G = (V,H, U, ΨH, ΨU ) is a function
g : H 7→ R+ such that g satisfies Kirchhoff’s law for metabolic graphs, i.e. for every
node v: ∑
h∈Γout(v)
Ψouth (v) · g(h) =
∑
k∈Γ in(v)
Ψ ink (v) · g(k) (1.9)
where Γ out(v) = {(X,Y ) ∈ H : v ∈ X}, Γ in(v) = {(W,Z) ∈ H : v ∈ Z}.
Definition 11. For a given flow g on a metabolic graph G, the amount of flow from
v0 to vn+1 is v(g) =
∑
h∈H,v0∈X g(h) =
∑
h∈H,vn+1∈Y Ψ
out
h (vn+1) · g(h).
Maximal Flow Problem. Consider a metabolic graph with a function c : H 7→ R+
assigning to each edge a maximal capacity. The maximal flow problem is defined
max(v(g)) such that g(h) ≤ c(h) for every h ∈ H. (1.10)
We are now ready to define a cut.
Definition 12. Consider a metabolic graph G = (V,H,U , ΨH, ΨU ). Given S, T ⊂ V ,
we define H(S, T ) = {(X,Y ) ∈ H : X ∩ S 6= ∅ and Y ∩ T 6= ∅}, as the set of edges
connecting nodes of S to nodes of T .
Given a flow g on G, the total flow from nodes in S to nodes in T is defined by:
g(S, T ) =
∑
h=(X,Y )∈H(S,T ),i∈Y ∩T
αih.
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Definition 13. Consider a metabolic graph G = (V,H,U , ΨH, ΨU ) with source v0,
and sink vn+1. Let S ⊂ V ∪ v0 be a set such that v0 ∈ S and vn+1 /∈ S and define
T = (V ∪ {vn+1}) \ S. Then the set of hyperedges CS = H(S, T ) is called a cut
separating v0 from vn+1. The capacity of the cut is defined by:
c(CS) =
∑
h∈CS
c(h). (1.11)
Notice that the capacity of the branch of hyperedge h adjacent to a node v can be
written as c(h) · αv.
The max flow of a directed graph is not necessarily unique. For a graph with a
directed cycle, the flow on the cycle can be increased (capacity permitting) without
violating Kirchoff’s law, or changing the total flow through the graph. For example,
the directed graph in Figure 1.3 (left) admits the maximal flow defined by setting
the flow on edges (s,1),(1,2),(2,3) and (3,t) equal to 10 while the flow on (4,1),(3,4)
equal to 0. However, the maximal flow can also be achieved setting (s,1),(3,4),(4,1)
and (3,t) to 10 while the flow on (1,2),(2,3) to 20. Often when computing maximum
flow on directed graph the flow through cycles is eliminated. In a metabolic graph
with hyperedges, flow through cycles may be unavoidable. The metabolic graph in
1.3 (right) contains one hyperedge, with branches that are equally weighted, one
of them leading to a sink, while the other leads to a cycle. This network admits a
unique maximum flow. This is produced by setting (s,1),(3,4),(4,1) to 10 while the
flow on (1,2),(2,(3,t)) to 20. Note that setting the flow (2,(3,t)) to 20 will cause 10
to flow to t and 10 to flow to 3 due to this hyperedge having equal weighting to its
branches.
s 1 2
34
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∞
∞
∞
∞
10
s 1 2
34
t
2010
∞
∞
∞
Fig. 1.3: A directed graph (left) and a metabolic graph (right) with similar structure.
Capacities are listed on edges and the hyperedge has a 1:1 ratio of flow for the two
branches, i.e., 10 units flow across each branch. The maximum flow for each graph
is 10, however the metabolic graph has a unique solution while the directed graph
does not.
We are now ready to state the following:
Lemma 1. Given a flow g from v0 to vn+1, and a cut CS separating v0 from vn+1,
it holds: v(g) ≤ c(CS)
Proof. Fix a flow g and a cut CS separating v0 from vn+1. The amount of flow v(g)
is equal to the flow entering the graph, equivalently the amount of flow entering S.
We also have v(g) will equal the transfer of flow from S to T ,
v(g) = g(S, T )− g(T, S).
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Since flows are positive we have
g(S, T )− g(T, S) ≤ g(S, T ) =
∑
h=(X,Y )∈CS ,i∈Y ∩T
αih ≤
∑
h∈CS
h = c(CS).
uunionsq
Since Lemma 1 applies to every flow g and cut CS , we can take the maximum over
all flows and the minimum over all cuts to obtain
max(v(g)) ≤ min(c(S)). (1.12)
The following Proposition shows that, as for simple graphs, an equality holds in
(1.12).
Proposition 3. (Max-flow-min-cut for Metabolic graphs) Formula (1.12) holds with
equality sign, i.e.:
max(v(g)) = min(CS)
Proof. Take a flow g such that v(g) is maximal. We construct a cut starting from
the intake nodes by recursion. Define S0 = I to be all intake nodes of the metabolic
graph. At each step ν, we define Sν+1 from Sν as follows:
1. If v ∈ Sν then v ∈ Sν+1,
2. if v1, v2 ∈ Sν , w ∈ V and there exists a hyperedge h = (X,Y ) such that v ∈
X,w ∈ Y and g(h) < c(h) or w ∈ X, v2 ∈ Y and g(h) > 0,then w ∈ Sν+1,
3. if v1, v2 ∈ Sν and there exists a hyperedge h = (X,Y ) such that v1 ∈ X, v2 ∈ Y ,
then for all w ∈ Y , w ∈ Sν+1
Clearly there will only be a finite number of steps until Sν is stable, i.e. no more
edges will be added after the ν¯ − th step. We define S = Sν¯ and T = V \ S.
We claim that vn+1 /∈ S. Assume, by contradiction that there exists a path vi1 , ..., vil
such that vi1 = v0, vil = vn+1. Then define for k = 1, ..., l − 1,
k = max

∑
h=(X,Y ):vik
∈X,vik+1∈Y
(c(h)− g(h)),
∑
h=(X,Y ):vik+1
∈X,vik∈Y
g(h)
 > 0
and  = mink k. We now define a new flow g˜ to reach a contradiction as follows. If
k =
∑
h=(X,Y ):vik
∈X,vik+1∈Y
(c(h)− g(h)), then for each h ∈ K1 we set
g˜(h) = g(h) + .
Otherwise we set
g˜(h) = g(h)− .
By construction g˜ is a flow, moreover v(g˜) = v(g)+. Then we reach a contradiction
for the maximality of v(g).
Define the cut CS = H(S, T ). Then the flow from v0 to vn+1 satisfies v(g) = g(S, T )−
g(T, S). Since g is maximal, we have g(T, S) = 0 and g(S, T ) =
∑
h∈CS (g(h)) =∑
h∈CS c(h) = c(CS). Therefore we have v(g) = c(S). uunionsq
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Definition 14. Given a metabolic graph with intakes, the vector φ¯ represents the
intake flows to each node, i.e. φ¯i = fh(v0,vi) if vi is an intake node and φ¯i = 0
otherwise.
Proposition 4. Given a system satisfying (H2), fix an x ∈ (R+)n and intake flow
vector φ¯ with strictly positive entries. There exists f ∈ (R+)m in the null space of
S(x) if and only if for each intake there exists a path to an excretion.
Proof. Consider the maximum flow problem on the metabolic graph G, where intake
edges hI have capacity φ¯, and all other edges have infinite capacity. The feasible flows
ϕ for this network are in one-to-one correspondence with the equilibrium fluxes
f ∈ N (S(x))∩ (R+)m (where N (S(x)) indicates the kernel of the matrix S(x)) such
that fh ≤ φ¯ for all h ∈ hI . The correspondence is simply given by fh = ϕh for all
h ∈ hI and fh = ϕh/Fh(X) for all h = (X,Y ) ∈ H \ hI .
If for all h ∈ hI there is a path to an excretion, then the minimum cut is the
collection of all edges h ∈ hI . The maximum flow ϕ∗ then satisfies ϕ∗(hI) = φ¯, thus
also ensuring the existence of an equilibrium flux f∗ satisfying the same property.
If for some h ∈ hI there is no path to an excretion, then all feasible flows ϕ satisfy
ϕh = 0, and hence all equilibrium fluxes f
∗ satisfy f∗h = 0 which contradicts the
assumption. uunionsq
1 2
3
Fig. 1.4: In this metabolic graph node 2 acts as an inhibitor to an edge leaving
itself.
In [22] several Propositions guarantee boundedness of solutions and no periodic os-
cillation. Specifically, the main results are: (1) Trajectories are bounded if and only if
there exists an equilibrium with positive entries; (2) If trajectories are bounded, then
they approach an equilibrium set for t→∞. These conclusions are also true under
assumption (H1) for simple graphs, but not under assumption (H2) for metabolic
graphs.
We start providing a counterexample via a small system of three nodes and one
inhibitor, see Figure1.4. We assume (H2) to hold with F (xv) = xv for all nodes v,
K2(x2) =
{
1
3
((x− 6)2 + 5) x ≤ 6
5
3
6 < x,
and stoichiometric matrix given by
S =
−x1 0 x2 0x1 −x2 ·K2(x2) −x2 x3
0 x2 ·K2(x2) 0 −x3
 ,
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with flux vector f = [1, 3, 3, 2]. The structure is visualized in Figure 1.4. This exam-
ple will admit an oscillatory solution because x2 ·K2(x2) is not monotone increasing
and has a negative slope for 1
3
(12−√21) < x2 < 13 (12+
√
21). The example reduces
to the example given in Remark 2 of [22], where further details can be found.
Under assumption (H1) we have several additional conditions which relate to ex-
istence and uniqueness of equilibria. These results again depend on the structure
of the network as well as an additional constraint on the functions Fh. Adapted
from [22, Theorems 4 and 5] these are: (1) There exists an equilibrium with positive
entries for constant intakes if and only if for all v ∈ V there is a path to X such that
all edges in the path have limxv→∞He(xv) = +∞; (2) If there exists an equilibrium
with positive entries, and all v ∈ V connect to J , then the equilibrium is unique.
Even if we are able to relate the existence of equilibria to network structure via
Proposition 2 and 4), uniqueness of equilibria may fail without further assumption.
Moreover, computation of equilibria is highly nontrivial. Indeed, for a simple graph
with a single enhancer or inhibitor, we can write the dynamics as follows
x˙ = J1(f)η(x) + J2(f)k(x) + φ (1.13)
where J1 is the Jacobian matrix without the edges affected by inhibitor/enhancer,
J2 is a matrix with the edges affected by inhibitor/enhancer, ηi(x) = Fvi(xvi),
φi = f(v0,vi) if (v0, vi) ∈ E, and φi = 0 otherwise, and ki(x) = Kvj (xvj ) · Fvi(xvi)
if vj acts on an edge starting from vi. If another node acts as an inhibitor, as it
happens for the addition of drug to the system, the size of J1, J2 would be adjusted
accordingly. Clearly (1.13) in general does not have a unique solution and the com-
putation of solutions can not be done analytically.
1.4.1 Exploring the space of equilibria with inhibitors and
enhancers
In this Section we further explore the problem of uniqueness and stability of equi-
libria for networks with enhancers and inhibitors. First, we provide an example of
non-uniqueness and a condition to ensure uniqueness. Let us define two classes of
systems:
Class A. Enhancers and inhibitors act in cascade, see Figure 1.5 top.
Class B. Enhancers and inhibitors act in parallel, see Figure 1.5 bottom.
To precisely define Class A and Class B networks let us first define an uberpath and
strictly upstream on a metabolic graph G = (V,H,U , ΨH, ΨU ).
Definition 15. An uber-path is a sequence of nodes (vk1 , . . . , vkm) such that for
every i = 1, . . . ,m − 1 there is an hyperedge (X,Y ) ∈ H for which one of the
following holds: 1) vki ∈ X, vki+1 ∈ Y ; 2) (vki , (X,Y )) ∈ U , vki+1 ∈ X ∪ Y ; 3)
(vki+1 , (X,Y )) ∈ U , vki ∈ X ∪ Y .
Definition 16. A node v0 is upstream of node v1 if there exists a hyperpath from
v0 to v1. A node v0 is strictly upstream of node v1 if v0 is upstream of v1 and there
is no uberpath from v1 to v0.
Definition 17. A network is called a Class A if: 1) there exists a sequence of en-
hancers or inhibitors (vk1 , . . . , vkm) such that vki is strictly upstream of vkj for all
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Fig. 1.5: Two networks with inhibitors and enhancers. Class A (left): inhibitor/
enhancers behave sequentially: node 1 affects downstream f4 and so on. Class B
(right), inhibitors/enhancers act in parallel.
i < j; 2) all enhancers (and inhibitors) are strictly upstream of nodes connected to
hyperedges that they enhance (inhibit). Precisely, part 2. means if there exists e/i-
uberedge u = (vj , h
∗) with h∗ = (X,Y ) then vj must be strictly upstream of every
node v ∈ X ∪ Y .
Networks that are not Class A are called Class B networks.
The conditions of Class A allow the equilibrium state of v1 ∈ I to be determined
based on the inflow and outflow for v1. The magnitude of the edge affected by v1
at equilibrium state can then be calculated. This will allow v1 to be determined
at equilibrium. Class A networks allow the equilibrium states of all enhancers or
inhibitors to be calculated this way, which can determine all fluxes (even those
affected by uberedges) in the system. Once all fluxes are determined, then the steady
state of every node in the network can be calculated for this a unique steady state.
This is shown in next:
Proposition 5. For a Class A network with a given flux, if there exists an equi-
librium with positive entries, and all v ∈ V connect to J , then the equilibrium is
unique.
Proof. Let G be a Class A metabolic graph. Then there exists a sequence of n
enhancers or inhibitors (vk1 , . . . , vkm) ⊂ V with vki is strictly upstream of vki+1 ,
and therefore all nodes upstream of vk1 are unaffected by enhanced edges. It follows
that xk1 has a unique steady state determined by fluxes corresponding to incoming
and outgoing edges. According to (H2):
x˙k1 =
∑
h∈Γ in(vk1 )
Ψ inh (vk1)Fh(x)fh −
∑
h∈Γout(vk1 )
Ψouth (vk1)Fh(x)fh. (1.14)
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where we used the notation of Definition 10. If for all (X,Y ) ∈ Γ in we have X ⊂ I
then for all vi ∈ X we can write x˙i = fj0 −
∑
h∈Γout(vk1 )
Ψouth (vi)Fh(x)fh. This de-
termines the steady state for xi, hence all steady state quantities in equation (1.14)
are known and the unique steady state of xk1 is determined. The same can be ob-
tained by recursion if the nodes vi are connected to I by some path with hyperedges
not affected by enhancers or inhibitors, which is always the case because vk1 is the
first node acting as enhancer or inhibitor. Finally the value of xk1 is determined.
Similarly, vk2 may be the terminal node, or initial node for some edges that are not
affected by inhibitors or enhancers except possibly vk1 , for which the value of xk1 has
been determined. Denote the steady state value of xk1 as x¯k1 According to (H2), ei-
ther x˙k2 =
∑
h∈Γ in(vk2 )
Ψ inh (vk2)Fh(x)fh−
∑
h∈Γout(vk2 )
Ψouth (vk2)Fh(x)fh or x˙k2 =∑
h∈Γ in(vk2 )
Ψ inh (vk2)Fh(x)K(x¯k1)fh−
∑
h∈Γout(vk2 )
Ψouth (vk2)Fh(x)K(x¯k1)fh, with
enhancer terms K(x¯k1) inserted. Therefore the value of xk2 is also determined.
By recursion, we can determine the value of all enhancers and inhibitors nodes, and
therefore, all enhanced or inhibited fluxes are determined.Finally we can determine
uniquely the value of all metabolites and fluxes. uunionsq
Class B networks are not expected to have a unique equilibrium. For instance the
network of Figure 1.5 bottom with Fi,h(xi) =
xi
1+xi
and Ki,h(xi) =
1
1+xi
has
two possible equilibria with values for x2 given by
f3 x1
f1 (1+x1)
− 1 and f2 (1+x1)
f4−f2 (1+x1) .
Choosing f{i=1,...,7} = {1, 1, 12, 2, 2, 2, 2} the two equilibria have positive entries:
x˜ = { 1
2
, 3, 1, 1, 1} and x¯ = { 1
3
, 2, 1, 1, 1}, see Fig 1.6.
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Fig. 1.6: Simulations for the class B system in Fig. 1.5. Top: Starting near the
unstable equilibrium x˜, the system tends to the stable one x¯. Bottom: Basin of
attraction to x¯ in x1 − x2 space (marked with “X”) with filled blue circles for
convergent initial data and hollow black circles for divergent ones.
1.5 Modeling Tuberculosis with metabolic graphs
Here we focus on the synthesis of antibiotic network of MTB. Such a network is
shown in Figure 1.7 including the action of a set of antibiotics commonly used in
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Fig. 1.7: A subnetwork of the MTB synthesis of antibiotics. The drugs written
show how they affect reactions (+ enhances the enzyme, - inhibits)
cure of tuberculosis. The action of drugs on edges is solely due to regulation of the en-
zyme for the corresponding reaction. We see that a group of three drugs regulates an
enzyme for a reaction from node v1 to node v10, f(v1,v10) . In this case treatment with
any single drug (Amikacin, Capreomycin, or Clofazimine) will effect a single gene
called “Rv1475c.” Amikacin and Capreomycin will upregulate the gene, and Clofaz-
imine will down regulate the gene. For edge f(v3,v2), Clofazimine downregulates two
genes, both acting as enzymes for the corresponding reaction. For the excretion from
node v2 out of the subnetwork, four drugs (Amikacin, Clofazimine, Ethionamide,
and Isoniasid) all upregulate the gene Rv0211. The combination of downregulating
f(v3,v2), and upregulating the excretion from v2 will serve to lower the metabolite
represented by v2, namely Oxalacetic acid (chemical formula: C4H4O5). Figure 1.8
compares two regimens with Rifapentine, showing more effectiveness of thee daily
versus the weekly treatment on the biosynthesis of antibiotic network.
The dynamics of the biosynthesis of antibiotics network (Fig. 1.7) can be written as
(1.3), where S : R→M10×28 is a sparse matrix.

−x1 x10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 −x1 C1 −x1 x2 0 0 0 0
0 0 x3 −x2 −x2 C2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 x1 −x2 0 0 0 0
0 0 −x3 x2 0 0 0 0 0 0 −x3 x4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 x3 −x4 0 0 0 0 x5 −x4 0 0 0 0 0 0 0 0 C3 −x4
0 0 0 0 0 0 0 0 0 0 0 0 0 0 −x5 x6 −x5 x4 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 x7 −x6 x5 −x6 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 x8 −x7 0 0 0 0 −x7 x6 0 0 0 0 0 0 0 0 0 0 C4 −x7 0 0
0 0 0 0 0 0 −x8 x7 x9 −x8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 −x9 x8 0 0 0 0 0 0 0 0 −x9 x10 0 0 0 0 0 0 0 0
x1 −x10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 x9 −x10 0 0 0 0 0 0 0 0

(1.15)
We show a simulation of the MTB biosynthesis of antibiotics network (Figure
1.7) to illustrate what can happen. Figure 1.8 will converge to different periodic
solutions based on the dosage chosen. The left hand side of Figure 1.8 shows the
evolution with an hourly treatment of Rifapentine, and the right hand side shows
the evolution with a weekly treatment. Note that most metabolites in the system
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converge to the same equilibrium value, however the metabolite labeled “node 6”
has oscillations that are centered around a very different value depending on dosage.
0 200 400 600 800 1000 1200
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Node 1
Node 2
Node 3
Node 4
Node 5
Node 6
Node 7
Node 8
Node 9
Node 10
0 200 400 600 800 1000 1200
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Node 1
Node 2
Node 3
Node 4
Node 5
Node 6
Node 7
Node 8
Node 9
Node 10
Fig. 1.8: Evolution of MTB biosynthesis of antibiotics. The first 200 hours are
without drug, then results with (left) daily one hour treatment with Rifapentine
and (right) weekly treatment at a higher dose.
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A Appendix: Definitions for general metabolic
ubergraphs
For completeness, this section constructs a more general version of a directed hy-
pergraph, weighted directed hypergraph, and metabolic graph by building upon the
classical notions of a graph and hypergraph. For the following definitions, V is a set
of nodes, and P(S) is the power set of a set S.
Definition 18. A directed graph is a pair G = (V,E) where E is the set of ordered
pairs such as (vi, vj) with vi, vj ∈ V which indicates a directed edge, starting from
the initial node vi and pointing to the terminal node vj.
Definition 19. A weighted directed hyperedge is a couple H 3 h = (X,Y ) with
X ∈ P(V ) or X = {v0}, Y ∈ P(V ∪ {vn+1}), and corresponding weights Ψh : h 7→
(Ψouth , Ψ
in
h ) where Ψ
out
h : X 7→ R+ and Ψ inh : Y 7→ R+.
Definition 20. A weighted directed hypergraph G is an ordered triplet G = (V,H, ΨH)
where ΨH denotes the set of functions assigning weights to hyperedges, i.e. ΨH =
{Ψh : h ∈ H}.
As shown in Section 1.3, weighted directed hypergraphs are the right mathematical
object to describe biochemical reactions involving multiple compounds. Interestingly,
while the theory of (not directed) hypergraphs seems well developed [4, 35], directed
hypergraphs have been less explored in the literature.
We are now ready to introduce a general definition of ubergraphs. The concept
was introduced in [16], but the used definition appears to allow some pathological
examples, thus we provide an alternative definition below.
First, given a finite set of nodes V = {v1, . . . , vn} define recursively Pk as:
Pk = P
(
k−1⋃
i=0
Pi
)
\ {∅}, P0 = V (1.16)
Definition 21. A depth-k ubergraph U is a k + 1-tuple G = (U0 = V,U1, . . . , Uk)
where Ui ⊆ Pi is a finite set of uberedges and Ui ⊂ P
(⋃k−1
i=0 Ui
)
\ {∅}. We call an
element of Ui a depth-i uberedge.
Let us provide some details on such definition. First notice that a depth-1 Ubergraph
is a classical hypergraph. Indeed in this case P1 = P (V ) \ {∅} which is precisely the
definition of the set of hyperedges.
In [16] the definition was slightly different allowing ∅ as an hyperedge. However,
this give rise to the problem of the meaning in models of an empty heperedge. The
problem becomes more dramatic for general depth k ubergraphs. Another difference
is that we force Ui to be subset of P
(⋃k−1
i=0 Ui
)
\ {∅}. If this is not the case, then
we may have depth-k uberedges which connect uberedges of lower depths, without
them being included in the ubergraph, see the following discussion for depth-2 uber-
graphs.
Depth-2 ubergraphs contains more general uberedges than hypergraphs. More pre-
cisely, G = (V,U1, U2), where U1 is a set of hyperedges and U2 ⊂ P (V ∩ U1) \ {∅}.
Therefore u ∈ U2 is a set {vk1 , . . . , vkm , hi1,, . . . , hip} where vkl ∈ V and hil ∈ U1.
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A particular case would be an uberedge {v, h}, v ∈ V , h ∈ U2, which could model
an enhancer or inhibitor action of metabolite xv on the reaction represented by
the hyperedge h. Let us remark again the importance of restricting the condition
Ui ⊂ Pi to the more stringent we use. If we impose only U2 ⊂ P2 then we could
allow ubereges of the type {v, h} with h /∈ U1, thus allowing metabolites to affect
reactions which are not in the model.
Example 1. Given a set of three nodes V = {v1, v2, v3} we want to explore depth-2
ubergraphs. First P1 = P (V ) \ {∅} thus
P1 = {{v1}, {v2}, {v3}, {v1, v2}, {v1, v3}, {v2, v3}, {v1, v2, v3}}.
In other words P1 contains all loops around nodes vi, regular edges and the only
possible (strict) hyperedge {v1, v2, v3}. U1 is any subset of P1. The cardinality of P1
is 23 − 1 = 7, since it is the power set of V excluding the empty set.
P2 = P (V ∪ P1) \ {∅} contains all ubereges {vk1 , . . . , vkm , hi1,, . . . , hip}, with 0 ≤
m ≤ 3, 0 ≤ p ≤ 3, m+ p ≥ 1, vkl ∈ V and hil ∈ P1. P2, being a power set excluding
the empty set, has cardinality 23+2
3−1 − 1 = 210 − 1 = 1023. Notice that there are
objects not easily interpreted in P2, for instance the uberedge {{v1}}, that is the
uberedge which loops over the loop over v1.
Finally, the possible ubergraphs on three nodes are given by a triplet V,U1, U2. The
possible choices of U1 are among all subsets of P1 thus we do have 2
7 = 128. The
possible choices for U2, not taking into account U1, are given by 2
|P2| = 21023 (where
we used | · | to indicate the cardinality of a set). However, as explained above, the
admissible U2 may be chosen only as subsets of P (V ∪ U1) \ {∅} thus the possible
choices are 22
3+|U1|−1.
As shown above, the set of ubergraphs can be extremely complex and of high
cardinality. Moreover, not all uberedges can be easily interpreted. Thus on one side
we would like to restrict the definition to allows only objects with modeling meaning,
but on the other side a further generalization is necessary to allow directed hper and
uberedges, weights and signs. This is achieved by next definition.
Definition 22. A depth-k metabolic graph is an ubergraph with (nontrivial) directed
weighted hyperedges and (nontrivial) directed signed uberedges of depth greater than
or equal to 2. More precisely it is a k + 3-tuple G = (V,H, ΨH, U2, . . . , Uk, ΨU ) such
that the following holds: V is a finite set; H is the set of directed hyperedges (X,Y ),
X,Y ⊂ V , X,Y 6= ∅; ΨH = {Ψouth , Ψ inh }h∈H , Ψouth : X → R+, Ψ inh : Y → R+, is
the set of weights; for j = 2, . . . , k, Uj = (X,Y ) with X,Y ⊂ P
(⋃j−1
i=0 Ui
)
\ {∅},
X,Y 6= ∅; ΨU = {Ψ j}2≤j≤k with Ψ j : Uj → {−1,+1}.
Example 2. A depth-2 metabolic graph includes directed weighted hyperedges and
signed uberedges of the type (X,Y ) with X,Y containing nodes and hyperedges.
Such a type of uberedge may represent the enhancer or inhibitor action of a set of
metabolites and reactions (those in X) over another set of metabolites and reactions
(those in Y ).
A depth-3 metabolic graph may also include the action of a depth-2 uberedge over
another set of depth-2 ubderedges. This type of edges may represent the effect of a
part of a metabolic network over another one by molecular mechanisms which are
not known.
1 Metabolic graphs model drug action on MTB using LIFE 21
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